Report has it that there have been over six US cases of a “rare and severe” type of blood clot.
These reported cases are allegedly part of more than 6.8 million doses of Johnson & Johnson vaccine that was given out in the United States.
This development has triggered the US Centers for Disease Control and Prevention and the US Food and Drug Administration to recommend that United States takes a pause in the use of Johnson & Johnson’s Covid-19 vaccine.
In a statement made on Tuesday by the Principal Deputy Director of the CDC, Dr. Anne Schuchat and the Director of the FDA’s Center for Biologics Evaluation and Research, Dr. Peter Marks, the CDC will organize a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday.
Meanwhile, Johnson & Johnson also issued a statement on Tuesday where it stated that the company has decided to “proactively delay the rollout” of its vaccine in Europe.
Revealing that the company has been working closely with medical experts and health authorities, part of the statement showed that the organization supports the open communication of the information to healthcare professionals and the public.